Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials | Zendy

EzzeldinM Ibrahim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials

Author(s) -

EzzeldinM Ibrahim

Publication year - 2010

Publication title -

annals of thoracic medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.639

H-Index - 33

eISSN - 1817-1737

pISSN - 1998-3557

DOI - 10.4103/1817-1737.65047

Subject(s) - medicine , gefitinib , hazard ratio , oncology , lung cancer , population , randomized controlled trial , placebo , non small cell lung cancer (nsclc) , odds ratio , chemotherapy , performance status , cancer , confidence interval , epidermal growth factor receptor , pathology , alternative medicine , environmental health , a549 cell

Gefitinib, a small molecule tyrosine kinase inhibitor, showed a substantial effect as a salvage treatment for patients with advanced non-small cell lung cancer (NSCLC) who had failed prior chemotherapy. Subsequent phase III trials in previously untreated patients have failed to demonstrate such benefit. It was later reported that gefitinib had a positive outcome when used in selected population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research